85. McQuillan, D., Mullany, J., Parker, J., Mills, D., Sherrell, K. and Chapman, Т.Н., 2000. Drug Residues in Ambient Water: Initial Surveillance in New Mexico, USA. December 2000 Progress Report, http://www.nmenv.state.nm.us/gwb/drugs. html; Morelli, J., 2000. Are Our Medicines Tainting the Environment?
http://webmd.lycos.com/content/article/25/1728_58159?
86. McQuillan, D., Mullany, J., Parker, J., Mills, D., Sherrell, K. and Chapman, Т.Н., 2000. Drug Residues in Ambient Water: Initial Surveillance in New Mexico, USA. December 2000 Progress Report, http://www.nmenv.state.nm.us/gwb/drugs. html
87. The Royal Commission on Environmental Pollution, 2003. Chemicals in products: safeguarding the environment and human health.
88. Hamburger Umwelt Institute, 1997. Poor Design Practices – gaseous emissions form complex products.
89. Brown, S.K. and Cheng, M., 2000. Volatile Organic Compounds (VOCs) in New Car Interiors. Presented at the 35th International Clean Air & Environment Conference Sydney, 26–30 November 2000.
90. http://www.le.ac.uk/ieh
91. Clapp, R.W and others, 2005.
92. The Globe and Mail, November 22, 2002, page A5. Data point to breast-cancer risk. By Martin Mittelstaedt.
93. Newby, JA. and Howard, C.V, 2006. Environmental influences in cancer aetiology. Journal of Nutritional and Environmental Medicine; 2006, 1-59.
94. Clapp, R.W and others, 2005.
95. Birnbaum, L.S. and Fenton, S.E., 2003. Cancer and developmental exposure to endocrine disruptors.
96. www.obgyn.nct/newsrx/womens_health-Colorectal_Cancer-20001214-7.asp
97. http://info.cancerresearchuk.org/healthyliving/dietand-healthycating/ theepicstudy
98. www.ucdmc.ucdavis.edu/ucdhs/health/a-z/06BreastCancer/ doc06lowerisk.html
99. Epidem. 1994, 23 (6), 1133–1136.
100. Spurgeon, D., 2006. Vitamin D is associated with a lower risk of cancer.
101. Miller, WR. and Sharpe, R.M., 1998. Environmental oestro-gens and human reproductive cancers.
102. http://cis.nci.nih.gov/fact/3_13.htm
103. Gottlieb, Scott. 2002. Study supports evidence on oral contraception and breast cancer.
104. Writing Group for the Women’s Health Initiative Investigators. 2002. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women.
105. Collaborative Group on Hormonal Factors in Breast Cancer,
1997. Breast cancer and hormone replacement therapy.
106. Schairer, C., Lubin, J., Troisi, R., and others, 2000. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer
107. www.nih.gov/news/pr/nov2002/nichd-29.htm
108. Ross, R.K., Paganini-Hill, A., Wan, P.C. and others, 2000. Effective hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
92, 328–332. Schairer, C., Lubin, J., Troisi, R. and others. 2000.
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer
109.
110. Ernst, E (editor), 2001.
111. Lee, John R, 1999.
112. Cowan, L.D., Gordis, L., Tonascia, J.A. and Jones, G.S., 1981. Breast cancer incidence in women with a history of progesterone deficiency.
113. Hrushesky, WJ.M., 1996. Breast cancer, timing of surgery, and the menstrual cycle: call for prospective trial. /
114. Mohr, P.E., Wang, D.Y., Gregory, WM., Richards, M.A. and Fentiman, I.S., 1996. Serum progesterone and prognosis in operable breast cancer.
115. Butler, J., 2006.
116. Dibble, S.L. and others, 2002. Risk factors for ovarian cancer; lesbian and heterosexual women.
117. Ives, A. and Semmens, J., 2007. Pregnancy after breast cancer: population based study.
118. www.cancer.org/docroot/cri/content/cri_2_4_5x_what_hap-pens_after_treatment_5.asp?sitearea=cr